Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

WSD 0922

Next Previous
Drug Profile

WSD 0922

Alternative Names: BBB Penetrable EGFR/EGFRvIII Inhibitor WSD0922-FU; EGFR Mutant Inhibitor WSD0922-FU; WSD-0922; WSD-0922-FU

Latest Information Update: 31 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Wayshine Biopharma
  • Class Antineoplastics; Small molecules
  • Mechanism of Action ErbB receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • Phase I Astrocytoma; Brain metastases; Glioblastoma

Most Recent Events

  • 22 Jul 2026 Mayo Clinic plans a phase II trial for Glioblastoma (Combination therapy) in the USA (PO) in August 2026 , (NCT07708961)
  • 17 Apr 2026 Pharmacodynamics data from a preclinical study in Non-small cell lung cancer presented at the 117th Annual Meeting of the American Association for Cancer Research (AACR-2026)
  • 17 Oct 2025 Phase-I/II clinical trials in Non-small cell lung cancer (Combination therapy, Metastatic disease, Late-stage disease) in China (PO) (NCT07206498)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top